

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): September 26, 2016

Rennova Health, Inc.
(Exact Name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction of Incorporation)

001-35141
(Commission File Number)

68-0370244
(I.R.S. Employer Identification No.)

400 S. Australian Avenue, Suite 800, West Palm Beach, Florida
(Address of Principal Executive Offices)

33401
(Zip Code)

(561) 855-1626
(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01. Regulation FD Disclosure.

Attached to this report as Exhibit 99.1 is a presentation that Rennova Health, Inc. (the “Company”) may present to investors, analysts and others. The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d)

<u>Exhibit No.</u>	<u>Exhibit Description</u>
99.1	Presentation slides.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 26, 2016

RENNOVA HEALTH, INC.

/s/ Seamus Lagan

Seamus Lagan

Chief Executive Officer

(principal executive officer)

EXHIBIT INDEX

Exhibit No.	Exhibit Description
99.1	Presentation slides.

Renno**va**Health

Solutions Driven By Innovation

Nasdaq: RNVA

Diagnostics and Supportive Software
Solutions to Healthcare Providers

Sept 2016



Forward-Looking Statements and Non-GAAP Information

This presentation includes forward-looking statements about Rennova Health's anticipated results that involve risks and uncertainties. Some of the information contained in this presentation, including statements as to industry trends and plans, objectives, expectations and strategy for the combined businesses, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Rennova Health with the Securities and Exchange Commission. Rennova Health undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances, except to the extent required by applicable law or regulation.


Note: This presentation includes certain "Non-GAAP" financial measures as defined by SEC rules. As required by the SEC, we have provided a reconciliation of those measures to the most directly comparable GAAP measures on the Regulation G slide included as slide 20 of this presentation. Non-GAAP financial measures should be considered in addition to, but not as a substitute for, reported GAAP results.

Who We Are

Healthcare is Being Transformed



We have the technology



We have the science



We have the expertise



Headquartered in West Palm Beach, Florida Rennova Health (Nasdaq RNVA, RNVAZ) is a healthcare service provider offering a suite of integrated services including but not limited to, Diagnostics, EHR, Laboratory Information Systems software, cancer diagnostics interpretation and medical billing services. Our main business is our diagnostics service for Toxicology, Clinical, Hormone and Pharmacogenomics testing. Software and medical billing services have exited the development phase and are producing initial revenues

Highlights


- Approximately \$8M invested in our Laboratories in 2014 and 2015, with no further significant investment required to enable substantial increases in diagnostics testing.
- Approximately \$5M invested in our software products in 2014 and 2015. Investment is ongoing but products are complete and launched
- Clinical Laboratories in Florida, New Jersey, New Mexico and California
- We operate in a very sizable and well established market place
- Capable, experienced management team
- Focused strategic growth plan from a solid foundation
 - EHR & Practice Management product for Substance Abuse sector
 - Medical Billing services launched to customers
- Secured in-network contracts with a number of payers and secondary networks nationwide
- Significant opportunity for growth of core business revenues;
- Supportive software solutions provide additional revenue streams and a more sustainable relationship with our customers thereby widening our market entry points and ultimately reducing the historical number of 90% of total revenues being derived from diagnostics

Single Source Solution for Medical Providers

- The diagnostics sector has changed dramatically in the last few years
- Paper records and faxes meant different vendors to a medical provider could function side by side without communication
- Electronic platforms and integration have created a need for providers of solutions to communicate efficiently, accurately, automatically and fast
- Medical providers need more than just diagnostics; they need an increasing number of integrated and interoperable solutions to enable their business to function
- Our core business has historically been diagnostics:
 - Historically >90% of our revenue is from diagnostics
 - The focus on diagnostics combined with supportive software solutions means that is now changing
- Compliance needs have increased with an ever more demanding regulatory and payer environment

Rennova has positioned itself to maintain a sustainable long term relationship with medical providers by providing a number of essential products and services, creating efficiencies for the provider and benefiting from additional revenue for the provision of these services and products

Single Source Solution for Medical Providers



Our core business is diagnostics: Historically >90% of our revenue has been derived from diagnostics That is changing:

Recent Developments

Corporate

- Received net proceeds of approximately \$7.3M in July from a public offering of common shares and warrants
- Exchanged all Series C Convertible Preferred Stock and 6,451,611 RNVAW warrants with certain downside protection to Series G Convertible Preferred Stock and new warrants that do not have downside protection. This resulted in a derivative liability being reclassified into stockholders equity
- The Company now has no securities issued that offer downside protection to our share price or permit a variable rate conversion
- Reported increased revenue for our 2nd quarter
- Acquired ownership stake in Genomas, Inc., a provider of pharmacogenomics diagnostics and interpretation
- Repaid certain Notes with a derivative liability enabling the reclassification of the derivative liability into stockholders equity
- Exchanged approximately \$2.1M of indebtedness and other cash obligations to various related parties for common stock and warrants
- Received an additional 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement of \$1.00 without effecting a reverse split on the Company's shares
- Continued to consolidate our laboratories and create cost efficiencies and reductions across our business segments

Recent Developments

Clinical Laboratory Operations Segment

- Reported increased revenue in the 2nd quarter of 2016 compared to the 1st quarter
- Continue to experience the benefits of our stance on compliance in light of the current disruption in the toxicology sector – a major focus of our Clinical Laboratory Operations segment
- Continue to add new customers. We currently have 122 active laboratory customers
- Launched pharmacogenomics testing
- We now have Medicaid licenses in 23 States
- We now have 13 payer contracts with Insurance payers in a number of States allowing us to target our sales efforts toward medical providers who participate in these networks

Supportive Software Solutions Segment

- Our integrated software solution will create a much more sustainable relationship with our customers as a result of being a contracted service with monthly revenues
 - We continue to add new EHR clients. We currently have 58 contracted software clients with 38 of them currently active software clients
 - We continue to add customers to our medical billing. We currently have 11 active medical billing clients
- We continue to add products to our software offerings. Initial product launch is complete but further development and improvements will be ongoing into 2017

2015 Accomplishments

Completed Lab Development



Supportive Software Development



Nasdaq listing



Our Target Markets

Drug and Alcohol Rehabilitation

- Large and growing number of facilities in a fragmented market
 - Total market size estimated at \$35 Billion*
 - Large and growing number of facilities in a fragmented market
 - Between 14,500 to 16,700 outpatient clinics*
- Market growth from high demand:
 - Over 23 million Americans are addicted to alcohol and other drugs**
 - The number of Americans in addiction treatment ranges from 2.5 million to 4.1 million***
 - 3 to 5 million people who have a diagnostic addiction disorder warranting treatment will gain coverage through healthcare reform****
 - Six states currently require some form of urine toxicology testing for the treatment of substance abuse or opioid therapy, and at least nine other states recommend such testing in their medical treatment guidelines

Market Drivers

Lab Services Drivers

- Secular growth
- Compliance

Value-added services

- Efficiency
- Cost
- Revenue cycle management

Sources:

*IBIS World,

**The National Council on Alcoholism and Drug Dependency,

***SAMHSA,

****National Association of Alcoholism and Drug Abuse Counselors

Our Target Markets

Pain Management Sector

- Large and growing number of clinics in a fragmented market
 - Total Market Size – estimated at \$2-\$4 Billion*****
 - Private clinics in the U.S. estimated between 1,500 and 2,500*****
 - More than 6,800 doctors specialize in pain management and more than 600,000 doctors are licensed to prescribe pain medication*****
- Market growth from high demand:
 - Chronic pain affects an estimated 100 million Americans, or one-third of the U.S. population*****
 - Approximately 25 million people experience moderate to severe chronic pain with significant pain-related activity limitations and diminished quality of life*****
 - Between 5 to 8 million people use opioids for long-term pain management*****
 - In 2015, U.S. providers wrote 204 million prescriptions for opioid painkillers*****

Market Drivers

Lab Services Drivers

- Secular growth
- Compliance

Value-added services


- Efficiency
- Cost
- Revenue cycle management

Sources:

****National Association of Alcoholism and Drug Abuse Counselors
 *****The U.S. Addiction Rehab Market, Bharat Publication, *****NIH,
 *****IMS Institute for Healthcare Informatics.

***** U.S. Department of Justice and Federal Trade Commission, "Horizontal Merger Guidelines", August 2012,
 ***** National Institutes of Health "Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain", September 2014,
 ***** Champion Pain Care Corp 10-K filing and the U.S. Addiction Rehab Market, Bharat Publication

Rennova Health Licensing Map



Our Payers

- Initiated Medicaid Licensing & Third Party Payer Initiative in December 2015
 - Applied for Medicaid Licenses in 34 States
 - As of September 21, 2016, we possess Medicaid Licenses in 23 States
- Current Third Party Insurance Payer Contracts
 - Blue Shield of California
 - Coventry (National Contract)
 - Corvel
 - Multiplan
 - PrimeHealth
 - FedMed
 - HealthSmart
 - America's Choice Provider Network
 - Tricare – South (Humana Military)
 - Health Net Services (Tricare North)
 - Three Rivers Provider Network
 - Galaxy Health Network
 - WellCare of Kentucky Managed Care



Strategy



Long Term Strategy

Create a sustainable relationship with our customers to grow recurring revenue and provide value to our shareholders

How?

Build from a toxicology-focused company to:

1. A significant and diverse diagnostics business
2. Offering supportive software solutions that add value by generating sustainable customer relationships and revenue
3. Exploring and developing new opportunities to improve provider and patient experiences and outcomes.

Remain proactive to the needs of patients and medical providers.

2016 Goals

- Strengthen Core Diagnostic Business
 - Capitalize on recent disruption in toxicology sector
 - Increase Clinical testing
 - Grow Pharmacogenomics testing with Genomas
 - Launch DTC (direct to consumer) testing
- Accelerate Growth and/or Launch:
 - Supportive software product sales (EHR in Rehab sector)
 - Medical Billing services as an integrated service
 - Interpretation and decision support in cancer diagnostics directly to doctors and public
 - Investigate opportunities for cancer diagnostics leveraging Genomas capabilities



Clinical testing with advanced analyzers



Online Training Program Launch to Deliver Increased Sales

Program Objectives:

- Ensure consistency in messaging and information
- Provide effective and easy to use platform
- Make information accessible anytime and from anywhere
- Enable opportunity for monitoring and assessment



**Initially for sales reps, but to be expanded over time for all employees.
Goal is 100% training compliance.**

Business Development Opportunities

**Epinex Diagnostics,
Inc.**




**Diabetes and rapid
diagnostic tests for providers
& consumers**

Genomas



**Genomics based
diagnostics - drug
management solution**

History in Numbers



Select Income Statement Items

<i>(in thousands)</i>	<u>2013</u>	<u>2014</u>	<u>2015</u>	<u>6 Months 2015</u>	<u>6 Months 2016</u>
GAAP Net Revenue	\$ 41,889	\$ 57,928	\$ 18,393	\$ 23,030	\$ 4,933
Reserve for Aged Accounts Receivable	-	1,501	19,494	-	-
Adjusted Revenues	\$ 41,889	\$ 59,429	\$ 37,887	\$ 23,030	\$ 4,933
GAAP Pretax Income (Loss)	\$ 13,829	\$ 15,382	\$ (44,991)	\$ (3,150)	\$ (10,106)
Depreciation and Amortization	408	1,500	2,750	1,250	1,429
Interest Expense	475	514	2,690	1,048	3,061
Impairment of Goodwill and Intangibles	-	-	20,143	-	-
Gain on Change in Fair Value of Derivatives	-	-	(2,328)	-	(4,727)
Stock Compensation Expense	63	852	3,628	3,069	363
Reserve for Aged Accounts Receivable	-	1,501	19,494	-	-
Adjusted EBITDA	\$ 14,775	\$ 19,749	\$ 1,386	\$ 2,217	\$ (9,980)

Capitalization at September 22, 2016

As of September 22, 2016

Common Shares Outstanding	53,670,931
Common shares underlying Series G Preferred Stock	21,758,222
Dilutive Potential Shares:	
Stock Options @ WAVG ex. \$4.19	22,599,174
Convertible Debt	1,760,000
Warrants @ WAVG ex. \$0.44	35,146,062
<u>Total Dilutive Potential</u>	<u>59,505,236</u>
<u>Fully Diluted Common Shares Outstanding</u>	<u>134,934,389</u>

Rennova Management

Seamus Lagan CEO	<ul style="list-style-type: none">• 20 years experience in the restructuring, development and management of startup and small companies
Jason Adams CFO	<ul style="list-style-type: none">• CFO in behavioral health sector and Senior Financial Management of public companies
Victoria Nemerson, Esq. Corporate Counsel	<ul style="list-style-type: none">• 25 years experience as a trial and defense attorney in the healthcare sector
Steven Burdelski Chief Compliance Officer	<ul style="list-style-type: none">• 25 years with the FBI with responsibility for corporate and legal compliance to improve performance
Jack Seeley Marketing & Sales – Diagnostics sector	<ul style="list-style-type: none">• 14 years experience in toxicology and Former VP for Solstas Lab Partners (now Quest Diagnostics)
Al Lechner EVP of Sales, Software Solutions	<ul style="list-style-type: none">• 30 years with GE Healthcare• Responsible for healthcare technology & software sales
Sebastien Sainsbury Investor & Public Relations	<ul style="list-style-type: none">• Banking and wealth management and 10 years on the Board of AIG International

Board of Directors

<p>Thomas Mika Chairman of Rennova, CEO of CollabRx (subsidiary)</p>	<ul style="list-style-type: none"> • 10 years as Chairman and CEO of a Nasdaq listed Company • Oversaw a number of public offerings • Bachelor of Science degree in Microbiology, MBA Harvard
<p>Seamus Lagan CEO</p>	<ul style="list-style-type: none"> • 20 years experience in the restructuring, development and management of startup and small companies • Founder, investor and shareholder
<p>Christopher Diamantis Director</p>	<ul style="list-style-type: none"> • Chairman and CEO of Integrated Financial Settlements, Inc., a structured settlement consulting firm
<p>Michael Goldberg Director</p>	<ul style="list-style-type: none"> • 16 years as CEO of an AMEX-listed healthcare company that acquired 23 labs and 2 hospitals under his tenure
<p>Dr. Paul Billings Director</p>	<ul style="list-style-type: none"> • A nationally recognized expert on genomic and precision medicine. Has served as Chief Medical Officer or Director of some of the nation's largest health care companies
<p>Benjamin Frank Director</p>	<ul style="list-style-type: none"> • Retired lawyer and businessman who served as Chairman of the Board of the Healthcare District of Palm Beach County
<p>Robert Lee Director</p>	<ul style="list-style-type: none"> • 16 years as a Managing Director of Morgan Stanley Dean Witter • Managing Director of the M&A group at Morgan Stanley, where he worked closely with financial sponsors • Chairman of numerous audit committees

Highlights

- Approximately \$8M invested in our Laboratories in 2014 and 2015, with no further significant investment required to enable substantial increases in diagnostics testing.
- Approximately \$5M invested in our software products in 2014 and 2015. Investment is ongoing but products are complete and launched
- Clinical Laboratories in Florida, New Jersey, New Mexico and California
- We operate in a very sizable and well established market place
- Capable, experienced management team
- Focused strategic growth plan from a solid foundation
 - EHR & Practice Management product for Substance Abuse sector
 - Medical Billing services launched to customers
- Secured in-network contracts with a number of payers and secondary networks nationwide
- Significant opportunity for growth of core business revenues;
- Supportive software solutions provide additional revenue streams and a more sustainable relationship with our customers thereby widening our market entry points and ultimately reducing the historical number of 90% of total revenues being derived from diagnostics